Myelofibrosis Clinical Trials

A listing of Myelofibrosis medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

California

UPDATED

Duarte California 91010

A Phase 2 clinical study for patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

UPDATED

Stanford California 94305

A Phase 2 clinical study for patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

District of Columbia

UPDATED

Washington District of Columbia 20037

A Phase 2 clinical study for patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

Florida

UPDATED

Fort Myers Florida 33901

A Phase 2 clinical study for patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

UPDATED

St. Petersburg Florida 33705

A Phase 2 clinical study for patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

UPDATED

West Palm Beach Florida 33401

A Phase 2 clinical study for patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

Illinois

UPDATED

Chicago Illinois 60637

A Phase 2 clinical study for patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

Maryland

UPDATED

Baltimore Maryland 21229

A Phase 2 clinical study for patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

Michigan

UPDATED

Grand Rapids Michigan 49503

Patients are needed to participate in a clinical research study evaluating ASN002 Dose Escalation and ASN002 MTD

Mississippi

UPDATED

Jackson Mississippi 39216

Patients are needed to participate in a clinical research study evaluating ASN002 Dose Escalation and ASN002 MTD

Missouri

UPDATED

St. Louis Missouri 63110

A Phase 2 clinical study for patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

New York

UPDATED

New York New York 10029

A Phase 2 clinical study for patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

Oregon

UPDATED

Portland Oregon 97239

Patients are needed to participate in a clinical research study evaluating ASN002 Dose Escalation and ASN002 MTD

Pennsylvania

UPDATED

Philadelphia Pennsylvania 19111

Patients are needed to participate in a clinical research study evaluating ASN002 Dose Escalation and ASN002 MTD

Tennessee

UPDATED

Nashville Tennessee 37203

A Phase 2 clinical study for patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

Texas

UPDATED

Houston Texas 77030

Patients are needed to participate in a clinical research study evaluating ASN002 Dose Escalation and ASN002 MTD

UPDATED

San Antonio Texas 78229

Patients are needed to participate in a clinical research study evaluating ASN002 Dose Escalation and ASN002 MTD

Washington

UPDATED

Seattle Washington 98109

A Phase 2 clinical study for patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis

Australia

UPDATED

VIC Melbourne 3004

A clinical trial to evaluate treatments using PIM447, Ruxolitinib and LEE011 for patients with Myelofibrosis (INC424)

Canada

UPDATED

Montreal Quebec H3T 1E2

A clinical trial to evaluate treatments using PIM447, Ruxolitinib and LEE011 for patients with Myelofibrosis (INC424)

France

UPDATED

Paris 75010

A clinical trial to evaluate treatments using PIM447, Ruxolitinib and LEE011 for patients with Myelofibrosis (INC424)

Germany

UPDATED

Mainz 55131

A clinical trial to evaluate treatments using PIM447, Ruxolitinib and LEE011 for patients with Myelofibrosis (INC424)

UPDATED

Ulm 89081

A clinical trial to evaluate treatments using PIM447, Ruxolitinib and LEE011 for patients with Myelofibrosis (INC424)

Italy

UPDATED

Firenze FI 50134

A clinical trial to evaluate treatments using PIM447, Ruxolitinib and LEE011 for patients with Myelofibrosis (INC424)

Singapore

UPDATED

Singapore 119228

A clinical trial to evaluate treatments using PIM447, Ruxolitinib and LEE011 for patients with Myelofibrosis (INC424)

Spain

UPDATED

Barcelona Catalunya 08036

A clinical trial to evaluate treatments using PIM447, Ruxolitinib and LEE011 for patients with Myelofibrosis (INC424)

United Kingdom

UPDATED

London SE1 9RT

A clinical trial to evaluate treatments using PIM447, Ruxolitinib and LEE011 for patients with Myelofibrosis (INC424)